Published in Cell Cycle on June 06, 2007
Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet (2009) 12.44
Inducible re-expression of HEXIM1 causes physiological cardiac hypertrophy in the adult mouse. Cardiovasc Res (2013) 1.45
RNA polymerase II transcription elongation control. Chem Rev (2013) 1.27
BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells. Oncotarget (2015) 1.12
P-TEFb- the final frontier. Cell Div (2009) 0.98
Brd4 and HEXIM1: multiple roles in P-TEFb regulation and cancer. Biomed Res Int (2014) 0.97
Identification of HEXIM1 as a positive regulator of p53. J Biol Chem (2012) 0.94
P27(Kip1), regulated by glycogen synthase kinase-3β, results in HMBA-induced differentiation of human gastric cancer cells. BMC Cancer (2011) 0.85
Down-regulation of cardiac lineage protein (CLP-1) expression in CLP-1 +/- mice affords. J Cell Mol Med (2009) 0.83
The JAK-STAT pathway in hypertrophic stress signaling and genomic stress response. JAKSTAT (2012) 0.82
Importance of genetic background for risk of relapse shown in altered prefrontal cortex gene expression during abstinence following chronic alcohol intoxication. Neuroscience (2010) 0.80
Targeting MYC as a therapeutic intervention for anaplastic thyroid cancer. J Clin Endocrinol Metab (2017) 0.77
Hexim1, a Novel Regulator of Leptin Function, Modulates Obesity and Glucose Disposal. Mol Endocrinol (2016) 0.76
HEXIM1 induces differentiation of human pluripotent stem cells. PLoS One (2013) 0.76
Multiple Lytic Origins of Replication Are Required for Optimal Gammaherpesvirus Fitness In Vitro and In Vivo. PLoS Pathog (2016) 0.76
Use of a novel cytotoxic HEXIM1 peptide in the directed breast cancer therapy. Oncotarget (2016) 0.75
Functional Interaction between HEXIM and Hedgehog Signaling during Drosophila Wing Development. PLoS One (2016) 0.75
Ubenimex enhances Brd4 inhibition by suppressing HEXIM1 autophagic degradation and suppressing the Akt pathway in glioma cells. Oncotarget (2017) 0.75
Deregulation of KSHV latency conformation by ER-stress and caspase-dependent RAD21-cleavage. PLoS Pathog (2017) 0.75
International network of cancer genome projects. Nature (2010) 20.35
p53 in health and disease. Nat Rev Mol Cell Biol (2007) 11.33
p53 isoforms can regulate p53 transcriptional activity. Genes Dev (2005) 6.76
Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer (2009) 5.12
Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell (2004) 4.46
Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell (2008) 3.38
p53 isoform delta113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish. Genes Dev (2009) 2.57
Translating p53 into the clinic. Nat Rev Clin Oncol (2010) 2.55
The role of mutant p53 in human cancer. J Pathol (2010) 2.49
p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nat Cell Biol (2009) 2.46
Loss of function of def selectively up-regulates Delta113p53 expression to arrest expansion growth of digestive organs in zebrafish. Genes Dev (2005) 2.44
The DEAD box protein p68: a novel transcriptional coactivator of the p53 tumour suppressor. EMBO J (2005) 2.12
Transcription - guarding the genome by sensing DNA damage. Nat Rev Cancer (2004) 2.10
The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2. EMBO J (2007) 2.07
Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res (2005) 2.06
Cell type-specific responses of human cells to inhibition of replication licensing. Oncogene (2002) 1.91
In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer (2002) 1.84
Hypophosphorylation of Mdm2 augments p53 stability. Mol Cell Biol (2002) 1.68
Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents. Chem Biol (2010) 1.66
Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy. Cell Cycle (2009) 1.64
Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy. Oncotarget (2010) 1.62
Regulation of p53 by the ubiquitin-conjugating enzymes UbcH5B/C in vivo. J Biol Chem (2004) 1.61
Structural and biochemical studies of human proliferating cell nuclear antigen complexes provide a rationale for cyclin association and inhibitor design. Proc Natl Acad Sci U S A (2005) 1.57
Identification of p53 regulators by genome-wide functional analysis. Proc Natl Acad Sci U S A (2004) 1.48
Ubiquitination of HEXIM1 by HDM2. Cell Cycle (2009) 1.46
Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosis. EMBO J (2009) 1.45
Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin. Clin Cancer Res (2008) 1.44
Suppression of the deubiquitinating enzyme USP5 causes the accumulation of unanchored polyubiquitin and the activation of p53. J Biol Chem (2008) 1.43
Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors. J Med Chem (2010) 1.32
Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-kappaB pathways. Nat Rev Drug Discov (2008) 1.30
p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients. Breast Cancer Res (2011) 1.29
Nutlin-3 inhibits the NFkappaB pathway in a p53-dependent manner: implications in lung cancer therapy. Cell Cycle (2007) 1.28
Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome. Oncotarget (2011) 1.27
Molecular simulations of protein dynamics: new windows on mechanisms in biology. EMBO Rep (2008) 1.25
Reactivation of p53: from peptides to small molecules. Trends Pharmacol Sci (2010) 1.25
p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes. J Clin Invest (2013) 1.21
Multiple peptide conformations give rise to similar binding affinities: molecular simulations of p53-MDM2. J Am Chem Soc (2008) 1.16
Positive feedback between p53 and TRF2 during telomere-damage signalling and cellular senescence. Nat Cell Biol (2010) 1.14
Stapled peptides with improved potency and specificity that activate p53. ACS Chem Biol (2012) 1.14
Small-molecule inhibitors of the p53 suppressor HDM2: have protein-protein interactions come of age as drug targets? Trends Pharmacol Sci (2004) 1.13
In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Clin Cancer Res (2005) 1.11
P14ARF promotes accumulation of SUMO-1 conjugated (H)Mdm2. FEBS Lett (2002) 1.10
Insights into cyclin groove recognition: complex crystal structures and inhibitor design through ligand exchange. Structure (2003) 1.09
Differential binding of p53 and nutlin to MDM2 and MDMX: computational studies. Cell Cycle (2010) 1.09
p14 Arf promotes small ubiquitin-like modifier conjugation of Werners helicase. J Biol Chem (2004) 1.07
MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism. BMC Cancer (2008) 1.06
Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit. Curr Med Chem Anticancer Agents (2003) 1.03
Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse. Mol Cancer Ther (2005) 1.03
Differences in the ubiquitination of p53 by Mdm2 and the HPV protein E6. FEBS Lett (2003) 1.03
Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination. Mol Cancer Res (2007) 1.03
Mutant p53 interactome identifies nardilysin as a p53R273H-specific binding partner that promotes invasion. EMBO Rep (2012) 1.03
Novel cambinol analogs as sirtuin inhibitors: synthesis, biological evaluation, and rationalization of activity. J Med Chem (2009) 1.02
Nucleophosmin interacts with HEXIM1 and regulates RNA polymerase II transcription. J Mol Biol (2008) 1.01
Def defines a conserved nucleolar pathway that leads p53 to proteasome-independent degradation. Cell Res (2013) 1.00
Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors. Chem Biol (2004) 0.99
Influenza A viruses control expression of proviral human p53 isoforms p53β and Delta133p53α. J Virol (2012) 0.98
Modulation of p53 binding to MDM2: computational studies reveal important roles of Tyr100. BMC Bioinformatics (2009) 0.97
Modulation of the p53-MDM2 interaction by phosphorylation of Thr18: a computational study. Cell Cycle (2007) 0.97
Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop. Structure (2003) 0.96
Wild-type and mutant p53 mediate cisplatin resistance through interaction and inhibition of active caspase-9. Cell Cycle (2012) 0.96
Pilot screening programme for small molecule activators of p53. Int J Cancer (2005) 0.95
Effects of overexpression of X-box binding protein 1 on recombinant protein production in Chinese hamster ovary and NS0 myeloma cells. Biotechnol Bioeng (2008) 0.94
Identification of HEXIM1 as a positive regulator of p53. J Biol Chem (2012) 0.94
The p53 isoforms are differentially modified by Mdm2. Cell Cycle (2012) 0.94
Using targeted transgenic reporter mice to study promoter-specific p53 transcriptional activity. Proc Natl Acad Sci U S A (2012) 0.93
Potential use of pharmacological cyclin-dependent kinase inhibitors as anti-HIV therapeutics. Curr Pharm Des (2006) 0.92
Exploiting the p53 pathway for cancer diagnosis and therapy. Hematol J (2003) 0.91
Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted purine cyclin-dependent kinase 2 inhibitors prepared by parallel synthesis. Mol Cancer Ther (2004) 0.91
Differential scanning fluorimetry as secondary screening platform for small molecule inhibitors of Bcl-XL. Cell Cycle (2009) 0.91
Oligomerization of the human ARF tumor suppressor and its response to oxidative stress. J Biol Chem (2003) 0.91
Directed evolution of p53 variants with altered DNA-binding specificities by in vitro compartmentalization. J Mol Biol (2007) 0.90
Modulating the p53 pathway. Semin Cancer Biol (2010) 0.90
The electrostatic surface of MDM2 modulates the specificity of its interaction with phosphorylated and unphosphorylated p53 peptides. Cell Cycle (2007) 0.90
Crystallization of eIF4E complexed with eIF4GI peptide and glycerol reveals distinct structural differences around the cap-binding site. Cell Cycle (2009) 0.90
MDM4 downregulates p53 transcriptional activity and response to stress during differentiation. Cell Cycle (2011) 0.89
Phosphatase WIP1 regulates adult neurogenesis and WNT signaling during aging. J Clin Invest (2014) 0.89
Turning the key on p53. Nature (2004) 0.87
Chemical states of the N-terminal "lid" of MDM2 regulate p53 binding: simulations reveal complexities of modulation. Cell Cycle (2011) 0.87
Why is F19Ap53 unable to bind MDM2? Simulations suggest crack propagation modulates binding. Cell Cycle (2012) 0.87
The p53-Mdm2 pathway: targets for the development of new anticancer therapeutics. Mini Rev Med Chem (2003) 0.87
Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model. Int J Cancer (2009) 0.87
Regulation of XBP-1 signaling during transient and stable recombinant protein production in CHO cells. Biotechnol Prog (2010) 0.86
XBP-1, a novel human T-lymphotropic virus type 1 (HTLV-1) tax binding protein, activates HTLV-1 basal and tax-activated transcription. J Virol (2008) 0.86
Tumor susceptibility and apoptosis defect in a mouse strain expressing a human p53 transgene. Cancer Res (2006) 0.86
Characterization, chemical optimization and anti-tumour activity of a tubulin poison identified by a p53-based phenotypic screen. Cell Cycle (2008) 0.85
NPMc(+) AML cell line shows differential protein expression and lower sensitivity to DNA-damaging and p53-inducing anticancer compounds. Cell Cycle (2011) 0.84
Mapping the structural and dynamical features of multiple p53 DNA binding domains: insights into loop 1 intrinsic dynamics. PLoS One (2013) 0.84
p53 transcriptional pathways in breast cancer: the good, the bad and the complex. J Pathol (2010) 0.84
On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: a Brownian dynamics study. Cell Cycle (2013) 0.83
Dimerization of the core domain of the p53 family: a computational study. Cell Cycle (2009) 0.83
Differences in the transactivation domains of p53 family members: a computational study. BMC Genomics (2010) 0.83
Investigating peptide sequence variations for 'double-click' stapled p53 peptides. Org Biomol Chem (2014) 0.83
Stapled BH3 peptides against MCL-1: mechanism and design using atomistic simulations. PLoS One (2012) 0.83
The fluorescent two-hybrid assay to screen for protein-protein interaction inhibitors in live cells: targeting the interaction of p53 with Mdm2 and Mdm4. J Biomol Screen (2014) 0.82
Detecting and quantifying p53 isoforms at mRNA level in cell lines and tissues. Methods Mol Biol (2013) 0.81
Detecting p53 isoforms at protein level. Methods Mol Biol (2013) 0.81